Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Precemtabart tocentecan - Merck KGaA

Next Previous
Drug Profile

Precemtabart tocentecan - Merck KGaA

Alternative Names: M-9140

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; Merck KGaA
  • Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Colorectal cancer

Most Recent Events

  • 24 Apr 2026 EMD Serono Research & Development Institute with Merck KGaA plans to initiate a phase III PROCEADE-CRC-03 trial for Colorectal cancer (Metastatic disease, Monotherapy, Combination therapy, Second-line therapy) in the US and Germany (IV) in May 2026 (NCT07549412)
  • 31 Mar 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in China, Germany, Italy, Spain (IV) (NCT06710132)
  • 04 Mar 2026 Merck KGaA plans a phase-III trial for Colorectal cancer (Metastatic disease) in 2026 (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top